<SEC-DOCUMENT>0001125345-16-000073.txt : 20170120
<SEC-HEADER>0001125345-16-000073.hdr.sgml : 20170120
<ACCEPTANCE-DATETIME>20161201121447
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001125345-16-000073
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20161201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s0653d7222c4c4c0ca67fd19cc0e19659"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:77%;"></td><td style="width:23%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="macrogenicslogoa03.jpg" alt="macrogenicslogoa03.jpg" style="height:130px;width:209px;"></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9704 Medical Center Drive</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rockville, MD 20850</font></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">December 1, 2016</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">VIA EDGAR SUBMISSION</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mr. Jim B. Rosenberg</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Senior Assistant Chief Accountant</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Office of Healthcare and Insurance</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">U.S. Securities and Exchange Commission</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Division of Corporation Finance, Mail Stop 4546</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">100 F Street, N.E.</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Washington, D.C.  20549</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">Re:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">MacroGenics, Inc.</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">Form 10-K for Fiscal Year Ended December 31, 2015</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">Filed February 29, 2016</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">Form 10-Q for Quarterly Period Ended September 30, 2016</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">Filed November 2, 2016</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">File No. 001-36112</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dear Mr. Rosenberg:</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">Set forth below is MacroGenics&#8217; (the &#8220;Company&#8221;) response to your letter dated November 22, 2016 provided by the staff of the Division of Corporation Finance (the &#8220;Staff&#8221;) of the Securities and Exchange Commission (the &#8220;Commission&#8221;) to the Company regarding the Company&#8217;s Form 10-K for the fiscal year ended December 31, 2015 and the Company&#8217;s Form 10-Q for the quarterly period ended September 30, 2016.  For ease of reference, the text of the comment is reproduced in italics immediately preceding our response.  </font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Form 10-K for the Year Ended December 31, 2015</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Notes to Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Note 9 - Collaboration and Other Arrangements - Janssen Biotech, page F-19</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Your collaboration and license agreement with Janssen for the development and commercialization of MGD011, which was filed as Exhibit 10.25 to your Form 10-K/A for the year ended December 31, 2014, describes your participation on a Joint Steering Committee whose responsibilities appear to extend into the late stage clinical and commercialization phases of development.  Please explain to us your consideration of your participation on this committee when identifying the deliverables in your collaboration agreement and how this impacted your determination of the units of account.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Response:</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;text-indent:17px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The collaboration and license agreement with Janssen regarding MGD011 is a complex arrangement that primarily consists of two main components, namely: (a) completion by MacroGenics of pre-clinical activities and filing of an Investigational New Drug application with the FDA and (b) the grant of an exclusive license to Janssen along with transfer of the program.  As  part of our review of the MGD011 agreement, management reviewed their participation on a Joint Steering Committee (JSC) as a potential deliverable or separate unit of accounting under the agreement.  </font></div><div style="line-height:120%;text-align:left;padding-left:29px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;text-indent:17px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This JSC was designed to provide an efficient information-sharing mechanism, but, as described in greater detail below, substantive decision-making rights are primarily held by Janssen. In addition, in accordance with section 2.1(f), the JSC is designed to dissolve before product commercialization if neither the co-funding option nor the co-promotion option are exercised.</font></div><div style="line-height:120%;text-align:left;padding-left:29px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;text-indent:17px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In accordance with section 2.1(e) of the agreement, Janssen will designate the chairperson of the JSC.</font></div><div style="line-height:120%;text-align:left;padding-left:29px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;text-indent:17px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In addition, according to section 2.5 of the agreement, Janssen has final decision-making authority with respect to any matter related to the development or commercialization of product under the agreement. The only exceptions are to ensure that Janssen may not use this mechanism to override other contractual provisions. Specifically, Janssen may not exercise such final decision-making authority to:  (i) expand its rights or MacroGenics&#8217; obligations or reduce its obligations and MacroGenics&#8217; rights under the agreement, (ii) determine that they have fulfilled all obligations or MacroGenics&#8217; has breached its obligations under the agreement, (iii) make any decision that is expressly stated to require MacroGenics&#8217; approval or agreement or the approval or agreement of both parties, or (iv) resolve any dispute regarding whether a milestone event has been achieved or the amount of any royalties, profit sharing payments, or other payments owed by one party to the other party.</font></div><div style="line-height:120%;text-align:left;padding-left:29px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;text-indent:17px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">It should be noted that participation on the JSC is a right, not an obligation and was not a substantive bargained-for element of our arrangement with Janssen.  </font></div><div style="line-height:120%;text-align:left;padding-left:29px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;text-indent:17px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">For the reasons listed above, management determined that participation on the JSC would not be considered as a substantive deliverable under the agreement with Janssen. </font></div><div style="line-height:120%;text-align:left;padding-left:29px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Form 10-Q for the Quarterly Period Ended September 30, 2016</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Notes to Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Note 5 - Collaboration and Other Agreements - Janssen Biotech</font></div><div style="line-height:120%;text-align:left;padding-left:29px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">With respect to the Janssen collaboration and license agreement entered into during May of 2016 for the development and commercialization of MGD015, you disclose that the total arrangement consideration was allocated to the license and R&amp;D services using the best estimate of relative selling price method.  Please clarify whether your performance obligations related to the R&amp;D services have been fully completed.  If not, please explain your basis for recognizing the entire upfront payment of $75 million during the reporting period.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Response:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:29px;text-indent:17px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">As a part of our review of the MGD015 agreement with Janssen, management identified two deliverables:  a) delivery of the exclusive license to develop and commercialize MGD015 in the licensed territory; and b) research and development activities during the pre-clinical development period.   </font></div><div style="line-height:120%;text-align:left;padding-left:29px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;text-indent:17px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Management determined that both of these deliverables had standalone value and therefore were separated for the purposes of revenue recognition. It was determined that MacroGenics would allocate total arrangement consideration to each of these deliverables using the relative-selling-price method in accordance with ASC 605-25.</font></div><div style="line-height:120%;text-align:left;padding-left:29px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;text-indent:17px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The total arrangement consideration related to the two deliverables includes the $75 million upfront payment and future amounts to be paid by Janssen related to the research and development activities, which are estimated to approximate the selling price of those services (approximately $1 million).  Therefore, the revenue associated with the license fee ($75 million) was recognized upon delivery of the license to Janssen.  Revenue related to the research and development services will be recognized as those services are provided, separately from the license fee.</font></div><div style="line-height:120%;text-align:left;padding-left:29px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;text-indent:17px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Performance obligations under the MGD015 agreement have not yet been completed and are being paid for as services are performed.  These services are currently expected to be completed on or about December 31, 2016.</font></div><div style="line-height:120%;text-align:left;padding-left:29px;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">If you have any further questions or comments, or if you require any additional information, please contact me by telephone at (301) 354-2681 or by email at </font><font style="font-family:inherit;font-size:11pt;color:#0563c1;text-decoration:underline;">karrelsj@macrogenics.com</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Sincerely,</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ James Karrels&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">James Karrels</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Senior Vice President and Chief Financial Officer</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cc:&#160;&#160;&#160;&#160;Angela Connell, Accounting Branch Chief, U.S. Securities and Exchange Commission</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jacob Luxenburg, Staff Accountant, U.S. Securities and Exchange Commission</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scott Koenig, M.D., Ph.D., President and Chief Executive Officer</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Atul Saran, Senior Vice President and General Counsel</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lynn Cilinski, Vice President and Controller</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>macrogenicslogoa03.jpg
<TEXT>
begin 644 macrogenicslogoa03.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $% :,# 2(  A$! Q$!_\0
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(WW30
MUV(QBOFC]H+XCG7-4_X1^RDS9VK_ +]E/^LD]/H/YUZC\:/B(O@?PZ8K:7&J
M7@*0 'E1CYG_  _G7D/P)^';>+M=.L:A&9-/LY W[P9$TO7!]0.IJEW ]3^
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M@3\-U\*Z&-3O8\:I?*&.X<Q1]E^IZFO5E&WBFP%HHHJ0"BBB@ HHHH ****
M&2R")2Q!('I213+,H9#D&GE0W6LRZ633Y//A&8C]^,?S% &I14%O=)=1!XSD
M&IA[T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,RS1JZ-N5AD&F7MHM["T3]"/RK TF]?3;YK&<X4G /H: .GHI <TM !1110
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MM_:%F%8_O8_E;_&M>N M;@^'=>9)"?+W;6_W3T-=\C!E!!R* '4444 %%%%
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M4DN.V20/_9:H?LZZ;'=>*;VZ=<FWM_D]BQ _E5W]I*$C6=&G_@:!T'U# _\
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M=6_M[PUI>I[=GVRUCN-OIN4-C]:U:_7XR4HJ2V9^3RBXR<7N@HHHJB0HHHH
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M,#TI:** $P/2C ]*6B@!,>U%+10 F!Z48]J6B@ HHHH **** "BBB@ KP_\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ KP_\ :4^]H/TF_P#9*]PKP_\
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MB@ HHHH **** "BBB@ HHHH *\/_ &E/O:#])O\ V2O<*\/_ &E/O:#])O\
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MPM'-,+K4&&4M(3EOJQ_A'UKYF\=?$C5_'UUNO93':*V8[6,D(OU]3[U4\/\
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M5KS#96\)_P"F<2K_ "%7%4+T 'THN!\L:#^SGXGU0JUZ8-+B/7S6WO\ D/\
M&O4O"_[//A[0RDE]YFK7 YS-Q&#_ +H_K7J]%*X%:QT^VT^W6"V@CMXEX"1J
M% JQM'I2T4@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
##__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
